The PERCEPTIONS study surveyed full-time workers who were starting tirzepatide for obesity or overweight (n = 518) [1]. The guide to employer coverage of GLP-1 treatment looks at employer benefits more broadly. This survey reflects what these individual workers reported.
What did workers say about coverage?
Among respondents, 80.9% reported having employer-sponsored health insurance. Of those respondents, 55.9% said their plan covered obesity medication [1]. In the full sample, 52.3% said they would consider changing jobs to get coverage. Another 81.7% said coverage could increase job satisfaction.
Who do those answers represent?
The study recruited through clinical sites and specialist agencies. Everyone surveyed had already started tirzepatide. If you are checking whether your plan covers a GLP-1, look up the product and prescribing reason in your current plan. The study recorded intentions to change jobs and did not follow actual job changes in this analysis.